Clinical Trial

Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastatic Tumors

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study will enroll patients with metastatic malignancies. Tumor samples (fresh or formalin-fixed paraffin-embedded tissue specimens) will undergo RNA extraction and next-generation sequencing (RNA-seq). Once the raw data is obtained, the system will analyze the transcriptomic feature values (cancer-specific RNA transcripts and tissue-specific RNA transcripts) expressed in the tumor tissue samples to further predict tissue origin using a machine learning model. The output includes probabilities and confidence intervals for tissue origin.
Trial Details
NCT Number NCT07319949
Lead Sponsor Fudan University
Conditions Malignant Tumor With Metastasis, CUP
Enrollment 30 participants
Start Date 2026-01-15
Primary Completion 2026-10-13 (estimated)
Study Completion 2026-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-01-06